Lisaftoclax, also known as APG-2575, is an investigational small-molecule BCL-2 inhibitor developed for oncology research and drug development. It selectively targets the anti-apoptotic protein BCL-2, which plays an important role in regulating programmed cell death and the survival of certain cancer cells.
Lisaftoclax has the CAS Number 2180923-05-9, molecular formula C45H48ClN7O8S and molecular weight 882.42 g/mol. It is a chemically defined pharmaceutical research compound supplied as a solid for qualified research, analytical and drug-development applications.
Lisaftoclax is a selective BCL-2 inhibitor designed to interfere with the anti-apoptotic function of BCL-2 proteins. BCL-2 is involved in the regulation of mitochondrial apoptosis and can contribute to the survival of malignant cells when its activity is dysregulated.
Lisaftoclax is being investigated in oncology research, including studies involving hematological malignancies such as chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Its development status and potential applications should be evaluated according to current regulatory and clinical information.
Lisaftoclax selectively binds to the BCL-2 protein and interferes with its interaction with pro-apoptotic proteins. This mechanism can promote activation of the mitochondrial apoptotic pathway and increase programmed cell death in cells that depend on BCL-2 for survival.
Lisaftoclax can be characterized using validated chromatographic and spectroscopic analytical techniques. HPLC or other suitable chromatographic methods may be used for assay and related-substance determination, while appropriate spectroscopic techniques may be used for identity confirmation.
Quality control may include identity, assay, related substances, water content, residual solvents, elemental impurities and other applicable parameters according to the approved or agreed product specification.
Lisaftoclax should be stored in a tightly closed container under controlled pharmaceutical or research-material storage conditions. The material should be protected from excessive heat, moisture, direct light and contamination. Specific storage conditions should follow the applicable product specification and Certificate of Analysis.
Lisaftoclax may be supplied for qualified pharmaceutical research, drug discovery, formulation development, analytical testing and other research applications, subject to applicable regulatory requirements. Product specifications, Certificate of Analysis, packaging configuration and technical documentation should be confirmed according to the intended application.
Swapproop Drugs and Pharmaceuticals supports the sourcing and supply of specialty pharmaceutical research compounds such as Lisaftoclax for qualified research and development requirements. Customers can request product specifications, analytical documentation, Certificate of Analysis, packaging information and commercial details.
For Lisaftoclax API requirements in India, contact Swapproop Drugs and Pharmaceuticals for product availability and technical information.
Lisaftoclax has CAS Number 2180923-05-9, molecular formula C45H48ClN7O8S and molecular weight 882.42 g/mol. It is also known by the development code APG-2575 and is classified as an investigational small-molecule BCL-2 inhibitor.
Lisaftoclax is an investigational drug candidate and should not be presented as an approved treatment. Its clinical development has focused on oncology and hematological malignancies. Regulatory status, clinical development and approved indications should be verified using current regulatory and clinical sources before commercial or medical use.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 2.0% |